List of Protagonist Therapeutics patents

Patents where

Current Assignee

Name

Protagonist Therapeutics

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10501515 Hepcidin analogues and uses thereof	Patent 10501515 was granted and assigned to Protagonist Therapeutics on December, 2019 by the United States Patent and Trademark Office.	Protagonist Therapeutics	Protagonist Therapeutics	United States Patent and Trademark Office	10501515	December 10, 2019
‌ US Patent 10030061 Hepcidin analogues and uses thereof	Patent 10030061 was granted and assigned to Protagonist Therapeutics on July, 2018 by the United States Patent and Trademark Office.	Protagonist Therapeutics	Protagonist Therapeutics	United States Patent and Trademark Office	10030061	July 24, 2018
‌ US Patent 10442846 Hepcidin analogues and uses thereof	Patent 10442846 was granted and assigned to Protagonist Therapeutics on October, 2019 by the United States Patent and Trademark Office.	Protagonist Therapeutics	Protagonist Therapeutics	United States Patent and Trademark Office	10442846	October 15, 2019
‌ US Patent 10301371 Cyclic monomer and dimer peptides having integrin antagonist activity	Patent 10301371 was granted and assigned to Protagonist Therapeutics on May, 2019 by the United States Patent and Trademark Office.	Protagonist Therapeutics	Protagonist Therapeutics	United States Patent and Trademark Office	10301371	May 28, 2019
‌ US Patent 10196424 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases	Patent 10196424 was granted and assigned to Protagonist Therapeutics on February, 2019 by the United States Patent and Trademark Office.	Protagonist Therapeutics	Protagonist Therapeutics	United States Patent and Trademark Office	10196424	February 5, 2019
‌ US Patent 10023614 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases	Patent 10023614 was granted and assigned to Protagonist Therapeutics on July, 2018 by the United States Patent and Trademark Office.	Protagonist Therapeutics	Protagonist Therapeutics	United States Patent and Trademark Office	10023614	July 17, 2018
‌ US Patent 10035824 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases	Patent 10035824 was granted and assigned to Protagonist Therapeutics on July, 2018 by the United States Patent and Trademark Office.	Protagonist Therapeutics	Protagonist Therapeutics	United States Patent and Trademark Office	10035824	July 31, 2018
‌ US Patent 11041000 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases	Patent 11041000 was granted and assigned to Protagonist Therapeutics on June, 2021 by the United States Patent and Trademark Office.	Protagonist Therapeutics	Protagonist Therapeutics	United States Patent and Trademark Office	11041000	June 22, 2021
‌ US Patent 10941183 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases	Patent 10941183 was granted and assigned to Protagonist Therapeutics on March, 2021 by the United States Patent and Trademark Office.	Protagonist Therapeutics	Protagonist Therapeutics	United States Patent and Trademark Office	10941183	March 9, 2021
‌ US Patent 10059744 α4β7 thioether peptide dimer antagonists	Patent 10059744 was granted and assigned to Protagonist Therapeutics on August, 2018 by the United States Patent and Trademark Office.	Protagonist Therapeutics	Protagonist Therapeutics	United States Patent and Trademark Office	10059744	August 28, 2018
‌ US Patent 10407468 Methods for synthesizing α4β7 peptide antagonists	Patent 10407468 was granted and assigned to Protagonist Therapeutics on September, 2019 by the United States Patent and Trademark Office.	Protagonist Therapeutics	Protagonist Therapeutics	United States Patent and Trademark Office	10407468	September 10, 2019
‌ US Patent 9822157 Hepcidin analogues and uses thereof	Patent 9822157 was granted and assigned to Protagonist Therapeutics on November, 2017 by the United States Patent and Trademark Office.	Protagonist Therapeutics	Protagonist Therapeutics	United States Patent and Trademark Office	9822157	November 21, 2017
‌ US Patent 10278957 Opioid agonist peptides and uses thereof	Patent 10278957 was granted and assigned to Protagonist Therapeutics on May, 2019 by the United States Patent and Trademark Office.	Protagonist Therapeutics	Protagonist Therapeutics	United States Patent and Trademark Office	10278957	May 7, 2019
‌ US Patent 9624268 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases	Patent 9624268 was granted and assigned to Protagonist Therapeutics on April, 2017 by the United States Patent and Trademark Office.	Protagonist Therapeutics	Protagonist Therapeutics	United States Patent and Trademark Office	9624268	April 18, 2017
‌ US Patent 9809623 α4β7 peptide monomer and dimer antagonists	Patent 9809623 was granted and assigned to Protagonist Therapeutics on November, 2017 by the United States Patent and Trademark Office.	Protagonist Therapeutics	Protagonist Therapeutics	United States Patent and Trademark Office	9809623	November 7, 2017
‌ US Patent 11472842 Analogues of hepcidin mimetics with improved in vivo half lives	Patent 11472842 was granted and assigned to Protagonist Therapeutics on October, 2022 by the United States Patent and Trademark Office.	Protagonist Therapeutics	Protagonist Therapeutics	United States Patent and Trademark Office	11472842	October 18, 2022
‌ US Patent 11111272 α4α7 peptide monomer and dimer antagonists	Patent 11111272 was granted and assigned to Protagonist Therapeutics on September, 2021 by the United States Patent and Trademark Office.	Protagonist Therapeutics	Protagonist Therapeutics	United States Patent and Trademark Office	11111272	September 7, 2021
‌ US Patent 9714270 a4B7 integrin thioether peptide antagonists	Patent 9714270 was granted and assigned to Protagonist Therapeutics on July, 2017 by the United States Patent and Trademark Office.	Protagonist Therapeutics	Protagonist Therapeutics	United States Patent and Trademark Office	9714270	July 25, 2017
‌ US Patent 10626146 α4β7 thioether peptide dimer antagonists	Patent 10626146 was granted and assigned to Protagonist Therapeutics on April, 2020 by the United States Patent and Trademark Office.	Protagonist Therapeutics	Protagonist Therapeutics	United States Patent and Trademark Office	10626146	April 21, 2020
‌ US Patent 11884748 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases	Patent 11884748 was granted and assigned to Protagonist Therapeutics on January, 2024 by the United States Patent and Trademark Office.	Protagonist Therapeutics	Protagonist Therapeutics	United States Patent and Trademark Office	11884748	January 30, 2024
‌ US Patent 11753443 Conjugated hepcidin mimetics	Patent 11753443 was granted and assigned to Protagonist Therapeutics on September, 2023 by the United States Patent and Trademark Office.	Protagonist Therapeutics	Protagonist Therapeutics	United States Patent and Trademark Office	11753443	September 12, 2023
‌ US Patent 11840581 α4β7 thioether peptide dimer antagonists	Patent 11840581 was granted and assigned to Protagonist Therapeutics on December, 2023 by the United States Patent and Trademark Office.	Protagonist Therapeutics	Protagonist Therapeutics	United States Patent and Trademark Office	11840581	December 12, 2023

22 results

0 selected

22 results

0 selected